Gnosis launch of #EdenDx, first non-invasive, liquid-based #cytology test for early #endometrial #cancer detection. Using #cervical samples, it detects hypermethylation of CELF4 genes, with results available in 3–7 days. healthandpharma.net/edendx-noninva… #cancertest, #endometrialtest

A novel #radioimmunotherapy strategy has shown compelling efficacy in eliminating #ovariancancer stem cells in preclinical models, marking a major advance in efforts to address relapse and resistance in #ovarian #cancer. Published in #NuclearMedicine healthandpharma.net/radio-immunoth…

A Science Advances study reveals that #cancer cells hijack the stress-response protein #eIF2A to navigate through tissue—independent of protein synthesis. Targeting eIF2A may selectively block #melanoma spread without harming healthy cells. healthandpharma.net/metastasis-eif…

A new study found that 42% of #ovariancancer patients in #remission still harbored minimal residual disease (#MRD), undetectable by scans. MRD was linked to worse survival, PFS dropped from 23.8 to 7.4 months. #ctDNA testing revealed hidden #cancer ... healthandpharma.net/hidden-disease…

#FDA has granted accelerated approval to #Modeyso (#dordaviprone) as the first treatment for recurrent H3 K27M+ diffuse midline #glioma—an aggressive pediatric #braintumor. The oral therapy achieved a 22% ORR with a median response duration of 10.3 months healthandpharma.net/fda-jazz-modey…

#FDA has accepted Bristol Myers Squibb’s Priority Review application for #Breyanzi® (#lisocabtagene #maraleucel) as a potential first-in-class #CART #celltherapy for relapsed or refractory marginal zone #lymphoma (#MZL). healthandpharma.net/fda-breyanzi-c…

CLD-201 (#SuperNova), a novel #stemcell–based #oncolytic virus therapy, has received #FDA Fast Track designation for soft tissue #sarcoma—marking a pivotal step in its clinical development. Backed by IND clearance, #CLD201... healthandpharma.net/fda-oncolytic-…

#FDA has granted accelerated approval to #zongertinib for pretreated, HER2+ non–small cell #lungcancer (#NSCLC), based on results from Beamion LUNG1 trial. Zongertinib achieved a 75% objective response rate, with 58% maintaining response beyond 6 months. healthandpharma.net/fda-zongertini…

#FDA has granted priority review for #epcoritamab combination, with potential approval making it the first #bispecific antibody regimen for second-line follicular #lymphoma treatment. Epcoritamab (#Epkinly) combo achieving a 95.7% overall response rate. healthandpharma.net/fda-epcoritama…

A Penn Medicine study show that tailoring #chemotherapy doses based on #genetictesting can significantly improve safety for #gastrointestinal (GI) #cancer patients, cutting severe toxicities from 65% to 38% compared with standard dosing healthandpharma.net/genetic-testin…

#FDA granted Fast Track Designation to #birelentinib for R/R chronic lymphocytic #leukemia (#CLL) or small lymphocytic #lymphoma (#SLL) after ≥2 prior therapies. The agent achieved an 84.2% ORR, and an estimated 9-month response durability of 83.3%... healthandpharma.net/fda-fast-track…

🚨 Phase 3 EV-303 trial show that #PADCEV (#enfortumab vedotin) + #KEYTRUDA (#pembrolizumab) is the first regimen to significantly improve both event-free survival and overall survival in cisplatin-ineligible muscle-invasive #bladdercancer. healthandpharma.net/padcev-keytrud…

New findings show that transcription factor #CREB drives the progression from #alcohol-induced #pancreatic inflammation to #cancer, particularly in #KRAS+ cells. Deleting CREB markedly reduced precancerous lesions and preserved acinar cell function. healthandpharma.net/alcohol-pancre…

#FDA has approved #Papzimeos (#zopapogene imadenovec) the first non-replicating viral-based #immunotherapy for treatment of adult recurrent #respiratorypapillomatosis. In a pivotal trial 51% of patients remained surgery-free for 12 months post-treatment. healthandpharma.net/fda-viral-immu…

A novel #mRNA-based vaccine encoding #tumor-specific neoantigens significantly enhanced anti-PD1 therapy in #gastriccancer with peritoneal metastasis. In preclinical models, the vaccine alone prevented metastasis and when combined with #antiPD1 eradicated healthandpharma.net/mrna-vaccines-…

Researchers have developed a novel #cancer therapy using bacteria to deliver #oncolyticvirus into tumors evading immune detection. It employs tumor-targeting #bacteria as microscopic couriers to transport #virus past immune defenses, into #cancercells healthandpharma.net/bacteria-cloak…

🧬 One of the toughest challenges in acute myeloid #leukemia (#AML) treatment is relapse after #chemotherapy. A new study reveals that #RNAisoform RUNX1C acts as a molecular switch driving #chemoresistance by pushing leukemia cells into a dormant state. healthandpharma.net/rna-isoform-ru…

#SağlıkHukuku yayınımız, ‘Mesajınız Var: Yapılacak Olan Tıbbi Müdahaleye Onay Veriyorsanız Tıklayın!‘ / ‘Tıbbi Müdahaleye Rızanın Elektronik Ortamda Alınması‘ canlı söyleşimizde ‘#tıbbionam’ sorunun pek çok boyutunu konuşacağız. Kayıt ve katılım linki: medikalakademi.com.tr/webinar/sh-ona…

Elektronik Rızayı Tartışıyoruz.

Yarın akşam 20:00'de #SağlıkHukuku yayınımızda buluşalım: ‘Tıbbi Müdahaleye Onay' ve ‘Tıbbi Müdahaleye Rızanın Elektronik Ortamda Alınması‘ canlı söyleşimizde ‘#tıbbionam’ sorunun pek çok boyutunu konuşacağız. Kayıt ve katılım linki: medikalakademi.com.tr/webinar/sh-ona…